peginterferon alfa-2a [Pegasys]

Phase 3

00%

Phase 3

Development Phase

2

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

9mo

ROCHE⭐Phase 3

Placebo Phase 3 Results Expected

peginterferon alfa-2a [Pegasys]• Hepatitis C, Chronic230

Sep 28

00%

6mo

ROCHEPhase 2

Placebo Phase 2 Results Expected

peginterferon alfa-2a [Pegasys]• Hepatitis C, Chronic160

Jul 13

00%

Drug Information

Target Indication

Hepatitis C, Chronic

Clinical Trial

Last updated: 1/2/2026

Developer

ROCHE

Roche Holding AG

Related Pipeline

Anemia

Non-Small Cell Lung Cancer

Breast Cancer

Leukemia, Lymphocytic, Chronic, B-Cell

Choroidal Neovascularization